Our results finally identified a new set of novel biomarkers and important molecular targets, including 3 TF-target gene pairs (SP1-LSP1, SPI1-FCGR1A, and STAT1-FCGR1A), 3 structural proteins of NETs (MPO, ELANE, and CAMP), and 6 other hub proteins (TP53, IL4, HP, SOCS3, FOS, and CD86), which might play essential biological roles during the progression of VTE in OM patients. Here, CD86 is linked to ocular melanoma.